Minerva Neurosciences | NERV - Current Assets


Minerva Neurosciences reported $83.1M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.22B 128.53M Jun/2026
Adma Biologics USD 528.2M 17.03M Jun/2026
ALKERMES USD 1.52B 164.26M Jun/2026
Alterity Therapeutics Limited AUD 37.91M 15.92M Dec/2025
AstraZeneca USD 27.97B 1.65B Jun/2026
BioCryst Pharmaceuticals USD 484.68M 111.06M Jun/2026
Bristol-Myers Squibb USD 28.58B 1.37B Jun/2026
Cipla INR 241.47B 7.71B Mar/2026
Clal Biotechnology ILS 14.69M 1.95M Dec/2023
Compugen USD 137.28M 10.74M Mar/2026
CSL USD 11.85B 1000K Dec/2025
Eli Lilly USD 64.67B 9.84B Jun/2026
GlaxoSmithKline GBP 17.56B 202M Jun/2026
Grifols EUR 5.96B 316.31M Dec/2025
Halozyme Therapeutics USD 933.02M 70.01M Jun/2026
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
J&J USD 59.77B 601M Jun/2026
Merck USD 36.68B 1.66B Jun/2026
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Neurocrine Biosciences USD 1.64B 798.6M Jun/2026
Novartis USD 27.35B 744M Jun/2026
Novavax USD 771.1M 79.72M Jun/2026
Pfizer USD 41.36B 1.46B Jun/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sanofi EUR 31.52B 1.36B Jun/2026
Takeda JPY 3.15T 59.77B Jun/2026
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025